[HTML][HTML] iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling

X Qing, Y Chinenov, P Redecha… - The Journal of …, 2018 - Am Soc Clin Investig
X Qing, Y Chinenov, P Redecha, M Madaio, JJTH Roelofs, G Farber, PD Issuree, L Donlin
The Journal of clinical investigation, 2018Am Soc Clin Investig
Lupus nephritis (LN) often results in progressive renal dysfunction. The inactive rhomboid 2
(iRhom2) is a newly identified key regulator of A disintegrin and metalloprotease 17
(ADAM17), whose substrates, such as TNF-α and heparin-binding EGF (HB-EGF), have
been implicated in the pathogenesis of chronic kidney diseases. Here, we demonstrate that
deficiency of iRhom2 protects the lupus-prone Fcgr2b–/–mice from developing severe
kidney damage without altering anti-double-stranded DNA (anti-dsDNA) Ab production by …
Lupus nephritis (LN) often results in progressive renal dysfunction. The inactive rhomboid 2 (iRhom2) is a newly identified key regulator of A disintegrin and metalloprotease 17 (ADAM17), whose substrates, such as TNF-α and heparin-binding EGF (HB-EGF), have been implicated in the pathogenesis of chronic kidney diseases. Here, we demonstrate that deficiency of iRhom2 protects the lupus-prone Fcgr2b–/– mice from developing severe kidney damage without altering anti-double-stranded DNA (anti-dsDNA) Ab production by simultaneously blocking HB-EGF/EGFR and TNF-α signaling in the kidney tissues. Unbiased transcriptome profiling of kidneys and kidney macrophages revealed that TNF-α and HB-EGF/EGFR signaling pathways are highly upregulated in Fcgr2b–/– mice, alterations that were diminished in the absence of iRhom2. Pharmacological blockade of either TNF-α or EGFR signaling protected Fcgr2b–/– mice from severe renal damage. Finally, kidneys from LN patients showed increased iRhom2 and HB-EGF expression, with interstitial HB-EGF expression significantly associated with chronicity indices. Our data suggest that activation of iRhom2/ADAM17-dependent TNF-α and EGFR signaling plays a crucial role in mediating irreversible kidney damage in LN, thereby uncovering a target for selective and simultaneous dual inhibition of 2 major pathological pathways in the effector arm of the disease.
The Journal of Clinical Investigation